ImageneBio (NASDAQ:IMA) versus AC Immune (NASDAQ:ACIU) Head-To-Head Review

AC Immune (NASDAQ:ACIU) and ImageneBio (NASDAQ:IMA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.

Profitability

This table compares AC Immune and ImageneBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AC Immune	-245.32%	-100.17%	-28.36%
ImageneBio	N/A	-38.99%	-34.84%

Earnings & Valuation

This table compares AC Immune and ImageneBio”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$17.51 million	13.95	-$85.03 million	($0.54)	-4.44
ImageneBio	$800,000.00	58.88	-$45.35 million	($4.58)	-0.91

ImageneBio has lower revenue, but higher earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

AC Immune has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, ImageneBio has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for AC Immune and ImageneBio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1	0	3	1	2.80
ImageneBio	2	0	1	1	2.25

AC Immune currently has a consensus target price of $7.50, indicating a potential upside of 212.50%. ImageneBio has a consensus target price of $29.00, indicating a potential upside of 598.80%. Given ImageneBio’s higher possible upside, analysts clearly believe ImageneBio is more favorable than AC Immune.

Insider and Institutional Ownership

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 4.6% of AC Immune shares are owned by company insiders. Comparatively, 2.2% of ImageneBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

About ImageneBio

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.